Goldman Sachs Maintains Buy on Tenet Healthcare, Raises Price Target to $196
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Jamie Perse has maintained a Buy rating on Tenet Healthcare (NYSE:THC) and raised the price target from $173 to $196.
October 30, 2024 | 5:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Goldman Sachs has reaffirmed its Buy rating on Tenet Healthcare and increased the price target from $173 to $196, indicating a positive outlook.
The increase in price target from $173 to $196 by a reputable firm like Goldman Sachs suggests confidence in Tenet Healthcare's future performance, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100